T-cell Acute Lymphoblastic Lymphoma: Clinical Trials

8 trials for T-cell Acute Lymphoblastic Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 not yet recruiting, 2 recruiting, 2 unknown. 8 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Active not recruiting 2, Not yet recruiting 2, Recruiting 2, Unknown 2
Phase 21Not yet recruiting 1

Follow T-cell Acute Lymphoblastic Lymphoma: new trials by email Literature Review of T-cell Acute Lymphoblastic Lymphoma trials Research Report on T-cell Acute Lymphoblastic Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Universal 4SCAR7U Targeting CD7-positive Malignancies
Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302026-12-312026-11-02
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
CD7.CAR/28zeta T Cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Phase 1RecruitingBaylor College of Medicine272026-05-122026-05-18
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Daratumumab - T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
Phase 1RecruitingNew York Medical College302023-05-222026-09-11
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
CD7.CAR/28zeta CAR T cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Phase 1Active not recruitingBaylor College of Medicine452021-08-022026-10-02
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
CD7 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1UnknowniCell Gene Therapeutics202020-12-012021-06-22
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
ThisCART7 cells - T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma
Phase 1UnknownFundamenta Therapeutics, Ltd.302020-01-222021-11-19
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Phase 1Active not recruitingBaylor College of Medicine1042017-11-012026-11-04

Narrower conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (8)  ·  Leukemia, Myeloid, Acute (2)  ·  Lymphoma, T-Cell (2)  ·  Lymphoma (1)

Broader conditions

Hematologic Diseases (8)  ·  Hemic and Lymphatic Diseases (8)  ·  Immune System Diseases (8)  ·  Immunoproliferative Disorders (8)  ·  Leukemia (8)  ·  Leukemia, Lymphoid (8)  ·  Lymphatic Diseases (8)  ·  Lymphoproliferative Disorders (8)  ·  Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (8)  ·  Leukemia, Myeloid (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoma (1)

Interventions

daratumumab (1)

Sponsors

Baylor College of Medicine (3)  ·  Shenzhen Geno-Immune Medical Institute (2)  ·  Fundamenta Therapeutics, Ltd. (1)  ·  New York Medical College (1)  ·  iCell Gene Therapeutics (1)

Countries

China (4)  ·  United States (4)

Top investigators

Rayne Rouce, MD (3)  ·  LaQuisa Hill, MD (2)  ·  Allyson Flower, MD (1)  ·  Hongyu Zhang (1)  ·  Mitchell Cairo, MD (1)  ·  Troy Quigg, DO (1)  ·  Wang Xingbing (1)

Results publications

PMID 34274536, PMID 36086817, PMID 36858787

NIH funding

P50CA126752 (1)